Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
申请人:Arena Pharmaceuticals, Inc.
公开号:US09012478B2
公开(公告)日:2015-04-21
Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).
公式Ia的吡唑衍生物及其药物组成物可以调节PGI2受体的活性。本发明的化合物和药物组成物适用于以下治疗方法:肺动脉高压(PAH)及相关疾病;血小板聚集;冠状动脉疾病;心肌梗塞;短暂性脑缺血发作;心绞痛;中风;缺血再灌注损伤;再狭窄;房颤;血栓形成在血管成形术或冠状动脉旁路手术患者或患有房颤的个体中;动脉粥样硬化;动脉粥样硬化性血栓形成;哮喘或其症状;糖尿病相关疾病,如糖尿病周围神经病、糖尿病肾病或糖尿病视网膜病变;青光眼或其他眼部异常眼压疾病;高血压;炎症;银屑病;银屑病性关节炎;类风湿性关节炎;克罗恩病;移植排斥反应;多发性硬化症;系统性红斑狼疮(SLE);溃疡性结肠炎;缺血再灌注损伤;再狭窄;动脉粥样硬化;痤疮;1型糖尿病;2型糖尿病;败血症;慢性阻塞性肺疾病(COPD)。